Navigation Links
Osteoarthritis in Medical Technology

Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain

... was effective at decreasing the pain of knee osteoarthritis (OA) at 26 weeks. The study showed that EUFLEXXA ... in the other group (P=0.006). The percentage of osteoarthritis Research Society International (OARSI) responders ... in the U.S. for treatment of knee pain due to osteoarthritis (OA). EUFLEXXA(R) is indicated for patients who ...

Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study

... compared with placebo, in patients with osteoarthritis pain of the knee. Data from the 13-week ... as measured by the Western Ontario and McMaster osteoarthritis Index (WOMAC). In this study, patients on ... with placebo. "The disabling nature of osteoarthritis pain can greatly impact a person's life," said ...

ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity

... its anti-TNF alpha antibody fragment ESBA105 in osteoarthritis (OA). This double-blind, randomized, ... AG, commented, "As of today, no disease-modifying osteoarthritis drug exists, which is the key unmet need. OA is ... with various safety issues, is not justified for osteoarthritis patients. The molecular properties of ESBA105 are ...

Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain

... a recently completed positive study in chronic osteoarthritis pain of the knee. The decision does not ... clinical trials: one positive study in chronic osteoarthritis pain of the knee(i) and two studies(ii,iii), -- ... in the Treatment of Patients with osteoarthritis Knee Pain. Poster presented at the ...

NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study

... escalating doses of naproxcinod and naproxen in osteoarthritis (OA) patients with controlled hypertension. The ... represent a valuable treatment alternative for osteoarthritis patients," said Raymond Townsend, Professor of ... in a relevant population of chronically treated osteoarthritis patients with many cardiovascular risk factors ...

Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference

... effective treatment option for the symptoms of osteoarthritis of the knee, with an improved safety profile ... in the management of patients with symptomatic osteoarthritis involving joints accessible to these agents." ... in the U.S. and Canada with symptoms of primary osteoarthritis of the knee. Patients in this five-arm, ...

Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period

... Results of FLEXX Trial Presented at the osteoarthritis Research Society International's 2008 World ... presented results from the FLEXX Trial of osteoarthritis of the Knee, showing that EUFLEXXA(R) (1% sodium ... saline (IA-saline) for the relief of pain in knee osteoarthritis (OA) at 26 weeks. The results of the trial of 586 ...

NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect

... 3 study for naproxcinod in 1020 patients with osteoarthritis of the knee (the 302 study). Both doses of ... of the knee and the ongoing 303 study in osteoarthritis of the hip, in addition to the 302 study). ... is a side effect of particular concern in the osteoarthritis population. A post hoc pooled analysis of the ...

Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis

... new research findings on the genetics of osteoarthritis (OA) at the 2008 World Congress on Osteoarthritis, sponsored by the osteoarthritis Research Society International (OARSI). The 2008 World Congress on osteoarthritis takes place Sept. 18-21, 2008, at the Rome ...

New Research Shows Physical Therapy as Effective as Arthroscopic Knee Surgery

... the usefulness of arthroscopic surgery for osteoarthritis of the knee should encourage patients to consider ... the pain and stiffness of moderate to severe osteoarthritis of the knee as surgery. "This study offers hope ... supporting physical therapy for treatment of osteoarthritis of the knee, including: -- A report published ...

Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis

... French maritime pine tree, reduced overall knee osteoarthritis (OA) symptoms by 20.9 percent and lowered pain by ... Pycnogenol may help the joints to recover. With osteoarthritis cases on the rise, many are seeking ... traditional medication taken. The CDC estimates osteoarthritis affects 34 percent of all adults over the age of ...

Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study

... -- New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 ... significant improvement in pain associated with osteoarthritis of the knee according to the primary efficacy ... and the prevalence increases with age.(2) osteoarthritis of the knee is a common type of this disorder, ...

NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR

... Additional efficacy end points, like the Modified osteoarthritis Research Society International (OARSI) responder ... and naproxen- controlled trial, in patients with osteoarthritis of the knee. 918 eligible patients were ... old, with a clinical diagnosis of primary osteoarthritis of the knee of at least 3 months duration, ...

NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study

... clinical trial for naproxcinod, in patients with osteoarthritis of the hip (the 303 study). 810 patients have ... in the 301 phase 3 study, in patients with osteoarthritis of the knee (see press release of October 27, ... The 302 study for naproxcinod in patients with osteoarthritis of the knee (see press release of April 3, 2007) ...

Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

... with moderate to severe chronic pain due to osteoarthritis showed that the efficacy and tolerability of ... patients with moderate to severe pain due to osteoarthritis of the hip or knee. Patients had required ... Western Ontario and McMaster Universities (WOMAC) osteoarthritis Index of pain, stiffness and function. Plasma ...

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

... -- The 301 study was conducted in patients with osteoarthritis of the knee and has provided successful ... -- The 302 study started enrolling patients with osteoarthritis of the knee in the U.S. in April 2007 and the ... 2007 in the U.S. and Europe, in patients with osteoarthritis of the hip. This study is expected to ...

Osteoarthritis: Which Treatments Work and Which Don't?

... Findings appear in the February issue of osteoarthritis and Cartilage MT. LAUREL, N.J., Feb. 19 ... set of treatment recommendations for knee and hip osteoarthritis may help millions of people worldwide who live in ... recommendations appear in the February issue of osteoarthritis and Cartilage and can be found at ...

NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update

... (303) is a 13-week trial in patients with osteoarthritis of the hip. Patient enrollment in this trial is ... and safety trial in which 1020 patients with osteoarthritis of the knee have been enrolled at 150 clinical ... of drugs for treating the signs and symptoms of osteoarthritis and are the same as those used in the other two ...

Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis

... by Dr. Catherine Middleton-Hardie at the osteoarthritis Research Society International (OARSI) 2007 World Congress on osteoarthritis in Fort Lauderdale, Florida during the poster ... December 7 and Saturday, December 8, 2007, at the osteoarthritis Research Society International 2007 World ...

Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis

... acid (HA) for the relief of pain in patients with osteoarthritis (OA) of the knee at the American College of ... the U.S. for the treatment of pain caused by knee osteoarthritis and is indicated for a three-injection treatment ... weight hyaluronan for the treatment of osteoarthritis of the ....

Anesiva Defines Regulatory Pathway for Adlea with FDA

... with orthopedic surgeries and management of osteoarthritis pain in the knee. Trials underway include a Phase ... shoulder surgery, a Phase 2 / 3 trial in osteoarthritis of the knee, and the two Phase 3 trials mentioned ... option in the management of chronic osteoarthritis pain. Importantly, the prolonged analgesic effect ...

Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee

... is lacking for many common ways of treating osteoarthritis of the knee, including popular dietary ... benefits to relieve knee pain caused by osteoarthritis and improve physical functioning, appear to be no ... from the pain and reduced mobility caused by osteoarthritis of the knee," said AHRQ Director Carolyn ...

Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery

... with orthopedic surgeries and management of osteoarthritis pain in the knee. These include a Phase 2 trial ... shoulder surgery, a Phase 2 / 3 trial in osteoarthritis of the knee, and a Phase 3 trial in Total Knee ... option in the management of chronic osteoarthritis pain. Importantly, the prolonged analgesic effect ...

Applying Clinical Findings to the Practice of Medicine

... Osteoporosis ( http://orthoinfo.aaos.org/topic.cfm?topic=A00232 ) and osteoarthritis ( http://orthoinfo.aaos.org/topic.cfm?topic=A00227 ) Skeletal ... tendon-to-bone insertion," stated Dr. Thomopoulos. Osteoporosis and osteoarthritis Hiroshi Kawaguchi, MD, Ph.D. and co-authors at the University of ...

ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology

... ESBA105 is also being studied in other therapeutic indications such as osteoarthritis (OA). Earlier this year, ESBATech initiated a Phase I/IIa clinical study to explore clinical activity of ESBA105 in osteoarthritis of the knee. About Cataract Surgery A cataract is a clouding of ...

Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results

... with naproxcinod demonstrating clear efficacy in this difficult type of osteoarthritis patients and showing the same GI adverse event rate as placebo. The blood ... States, Canada and Europe. Eligible patients had a diagnosis of primary osteoarthritis of the hip of at least three months in duration and were randomized on a ...

Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting

... significant pain relief in patients with moderate to severe pain due to osteoarthritis of the hip or knee compared to placebo. Findings also showed that ALO-01 ... with placebo in 344 adult patients with moderate to severe pain due to osteoarthritis of the hip or knee. After a screening and washout period from previous ...

Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs

... were measured by Elecsys proBNP (Roche Diagnostics) in 433 patients with osteoarthritis of the knees, with or without osteoarthritis of the hands, during an observational period of 200 days. Cardiovascular ...

NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology

... from the first pivotal phase 3 trial for naproxcinod in patients with osteoarthritis of the knee (the 301 study) were presented on November 10, 2007 at the ... Anti-inflammatory Drugs (NSAIDs) or acetaminophen (paracetamol) for their osteoarthritis pain and these analgesics were withdrawn before treatment with study-drug. ...

The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement

... is a minimally invasive device intended to relieve pain caused by moderate osteoarthritis of the knee. "The interest from surgeons and patients for a minimally ... Knee Implant, is intended for the treatment of patients with moderate osteoarthritis of the medial compartment. The company received 510(k) clearance to market ...

Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results

... of osteoporosis and the other product relates to the prevention of osteoarthritis -- osteoarthritis product has the potential to be the first disease- modifying drug that ...

Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results

... of osteoporosis and the other product relates to the prevention of osteoarthritis -- osteoarthritis product has the potential to be the first disease- modifying drug that ...

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

... opioid treatment for an extended period of time; and VOLTAREN(R) Gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment such as those of the hands and the knees. Voltaren(R) Gel is owned and licensed by Novartis AG; SANCTURA(R) ...

Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density

... data from the second Phase III trial called "NEXT" study were presented at the European Society for Clinical and Economic Aspects of Osteoporosis and osteoarthritis (ECCEO) annual meeting. The third Phase III trial, the "GENERATIONS" Study, is a five-year, randomized, double-blind, placebo-controlled study ...

Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis

... worsening hot flushes in the arzoxifene group. The data were presented at the European Society for Clinical and Economic Aspects of Osteoporosis and osteoarthritis (ECCEO) annual meeting. Arzoxifene is being studied for the prevention and treatment of osteoporosis in postmenopausal women and the reduction ...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

... opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, ...

TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee

... allowance from the Korea Food and Drug Administration (KFDA) to initiate a Phase IIa clinical trial of TissueGene-C (TG-C) in patients with severe osteoarthritis of the knee. TG-C has been developed for the localized delivery of allogeneic human cells expressing TGF-beta1 in order to induce the regeneration ...

Kensey Nash Announces IDE Submission for Cartilage Repair Device

... the knee and a majority of these are repeat procedures, illustrating the ineffectiveness of current therapeutic approaches. Over time, debilitating osteoarthritis may develop in the afflicted joint ultimately requiring partial or total knee replacement. The Company believes that an early and successful ...

New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years

... edition of the specialist journal "Osteoarthritis and Cartilage". The researchers followed 376 patients to determine the effectiveness of various osteoarthritis treatments. After six months as well as after two years, patients who received Orthokine therapy experienced significantly less pain and more ...

Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments

... opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, ...
Other Contents
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
(Date:3/28/2015)... Take a bite of warm, gooey pepperoni pizza, and ... the stomach, ready to break down your meal. In ... run amok, triggering a burning sensation in the chest. ... million Americans have heartburn at least once a month. ... it can be stopped. , Heartburn or acid reflux ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New York ... commemorated its three-year anniversary of being the only 24/7 ... 24-hour urgent care, Emergency Medical Care offers its clients ... Emergency Medical Care’s Urgent Care NYC services ... injuries, ear infections, fevers, insect bites, burns, animal bites, ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 Pitching ... with a history of shoulder and elbow injuries, according to ... Sports Medicine’s ( AOSSM ) Specialty Day. , “Our findings ... with a 20% increase in likelihood of a history of ... associated with a 12% increase likelihood of a history of ...
(Date:3/28/2015)... Early surgery may not be the best ... injuries, according to new research from Tripler Army Medical ... Society for Sports Medicine’s ( AOSSM ) Specialty Day, ... was not performed. , The final study group focused ... 17 receiving non-surgical therapy. Of the non-surgery group, 8 ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
Breaking Medicine News(10 mins):Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
Other TagsOther Tags